Temozolomide and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Temozolomide (temozolomide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Epilepsy.

The phase IV clinical study analyzes which people have Mobility decreased when taking Temozolomide. It is created by eHealthMe based on reports of 16,598 people who have side effects when taking Temozolomide from the FDA, and is updated regularly.

What is Temozolomide?

Temozolomide has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 16,644 Temozolomide users. Check the latest studies of Temozolomide.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,778 drugs and 1,632 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Jul, 06, 2026

16,598 people reported to have side effects when taking Temozolomide.
Among them, 36 people (0.22%) have Mobility decreased.

Could Temozolomide cause Mobility decreased?

Among these 36 people:

How long have people been on Temozolomide when they have Mobility decreased? *

What is the gender of people who have Mobility decreased when taking Temozolomide? *

female: 46.43 %
male: 53.57 %

What is the age of people who have Mobility decreased when taking Temozolomide? *

What are other drugs people take besides Temozolomide? *

What are other side effects people have besides Mobility decreased? *

Weakness: 18 people, 50.00%
Pain: 17 people, 47.22%
Fall: 14 people, 38.89%
Fatigue (feeling of tiredness): 13 people, 36.11%
Malignant Neoplasm Progression (cancer tumour came back): 12 people, 33.33%
General Physical Health Deterioration (weak health status): 10 people, 27.78%
Confusional State: 10 people, 27.78%
Dyspnea (difficult or laboured breathing): 9 people, 25.00%
Speech Impairment (Adult) (inability to speak (adult)): 9 people, 25.00%
Hemiparesis (weakness on one side of the body): 8 people, 22.22%

What are the existing conditions these people have? *

Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 7 people, 19.44%
Osteoporosis (bones weak and more likely to break): 6 people, 16.67%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 6 people, 16.67%
Nausea (feeling of having an urge to vomit): 3 people, 8.33%
Carcinoid Tumor: 3 people, 8.33%
Neuroendocrine Tumor: 1 person, 2.78%
High Blood Pressure: 1 person, 2.78%
Glioma (a type of tumour that starts in the brain or spine): 1 person, 2.78%
Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Temozolomide and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temozolomide:

Temozolomide (16,644 reports)

Browse all side effects of Temozolomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,778 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,632 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on temozolomide (the active ingredients of Temozolomide) and Temozolomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.